Symbols / AVBP Stock $27.87 -1.94% ArriVent BioPharma, Inc.

Healthcare • Biotechnology • United States • NGM
AVBP (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Zhengbin Yao Ph.D.
Exch · Country NGM · United States
Market Cap 1.30B
Enterprise Value 972.08M
Income -145.24M
Sales —
FCF (ttm) -82.84M
Book/sh 7.15
Cash/sh 7.01
Employees 77
Insider 10d —
IPO Jan 26, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -8.36
PEG —
P/S —
P/B 3.90
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 13.06
Current Ratio 13.95
Debt/Eq 0.13
LT Debt/Eq —
EPS (ttm) -3.38
EPS next Y -3.33
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-05-11
ROA -34.72%
ROE -55.17%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 46.57M
Shs Float 30.10M
Insider Own 2.77%
Instit Own 90.62%
Short Float 16.33%
Short Ratio 13.97
Short Interest 7.11M
52W High 32.14
vs 52W High -13.29%
52W Low 16.10
vs 52W Low 73.11%
Beta 1.52
Impl. Vol. 1.29%
Rel Volume 0.58
Avg Volume 483.20K
Volume 278.48K
Target (mean) $41.94
Tgt Median $43.50
Tgt Low $25.25
Tgt High $50.00
# Analysts 12
Recom Strong_buy
Prev Close $28.42
Price $27.87
Change -1.94%
About

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$41.94
Mean price target
2. Current target
$27.87
Latest analyst target
3. DCF / Fair value
$-32.02
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$27.87
Low
$25.25
High
$50.00
Mean
$41.94

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-13 main Citigroup Buy → Buy $43
2026-04-24 main Citigroup Buy → Buy $45
2026-03-23 main B. Riley Securities Buy → Buy $45
2026-03-06 reit Oppenheimer Outperform → Outperform $50
2026-03-06 main Citigroup Buy → Buy $33
2026-03-06 main HC Wainwright & Co. Buy → Buy $44
2025-12-23 init Cantor Fitzgerald — → Overweight —
2025-12-10 init BTIG — → Buy $45
2025-11-25 init Truist Securities — → Buy $43
2025-11-11 main Citigroup Buy → Buy $31
2025-08-12 main HC Wainwright & Co. Buy → Buy $42
2025-08-12 main Citigroup Buy → Buy $33
2025-07-22 reit HC Wainwright & Co. Buy → Buy $40
2025-06-25 init Clear Street — → Buy $32
2025-06-24 main Oppenheimer Outperform → Outperform $44
2025-06-24 reit Guggenheim Buy → Buy $45
2025-05-20 init Jones Trading — → Buy $40
2025-05-14 main HC Wainwright & Co. Buy → Buy $40
2025-03-20 init B. Riley Securities — → Buy $37
2025-03-10 init Guggenheim — → Buy $45
News
RSS: Latest AVBP news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-10 HILLHOUSE INVESTMENT MANAGEMENT, LTD. Beneficial Owner of more than 10% of a Class of Security — 555,555 $23.37 $12,983,320
2025-07-11 LACHAPELLE ROBIN Chief Operating Officer — 11,153 $2.28 $25,429
2024-09-19 LACHAPELLE ROBIN Chief Operating Officer — 27,566 $2.28 $90,481
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
177.53
+88.25%
94.31
+26.44%
74.59
+102.11%
36.91
Research And Development
153.35
+94.11%
79.00
+21.76%
64.88
+113.20%
30.43
Selling General And Administration
24.18
+58.02%
15.30
+57.68%
9.71
+49.95%
6.47
General And Administrative Expense
24.18
+58.02%
15.30
+57.68%
9.71
+49.95%
6.47
Other Gand A
24.18
+58.02%
15.30
+57.68%
9.71
+49.95%
6.47
Total Expenses
177.53
+88.25%
94.31
+26.44%
74.59
+102.11%
36.91
Operating Income
-177.53
-88.25%
-94.31
-26.44%
-74.59
-102.11%
-36.91
Total Operating Income As Reported
-177.53
-88.25%
-94.31
-26.44%
-74.59
-102.11%
-36.91
EBITDA
-177.53
-88.25%
-94.31
-26.44%
-74.59
-102.11%
-36.91
Normalized EBITDA
-177.53
-88.25%
-94.31
-26.44%
-74.59
-102.11%
-36.91
EBIT
-177.53
-88.25%
-94.31
-26.44%
-74.59
-102.11%
-36.91
Net Income
-166.31
-106.62%
-80.49
-16.09%
-69.33
-87.86%
-36.91
Pretax Income
-166.31
-106.62%
-80.49
-16.09%
-69.33
-87.86%
-36.91
Net Non Operating Interest Income Expense
11.23
-18.77%
13.82
+162.89%
5.26
0.00
Net Interest Income
11.23
-18.77%
13.82
+162.89%
5.26
0.00
Interest Income Non Operating
11.23
-18.77%
13.82
+162.89%
5.26
0.00
Interest Income
11.23
-18.77%
13.82
+162.89%
5.26
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-166.31
-106.62%
-80.49
-16.09%
-69.33
-87.86%
-36.91
Net Income From Continuing Operation Net Minority Interest
-166.31
-106.62%
-80.49
-16.09%
-69.33
-87.86%
-36.91
Net Income From Continuing And Discontinued Operation
-166.31
-106.62%
-80.49
-16.09%
-69.33
-87.86%
-36.91
Net Income Continuous Operations
-166.31
-106.62%
-80.49
-16.09%
-69.33
-87.86%
-36.91
Normalized Income
-166.31
-106.62%
-80.49
-16.09%
-69.33
-87.86%
-36.91
Net Income Common Stockholders
-166.31
-106.62%
-80.49
-16.09%
-69.33
-87.86%
-36.91
Diluted EPS
—
-2.56
-17.99%
-2.17
-87.86%
-1.15
Basic EPS
—
-2.56
-17.99%
-2.17
-87.86%
-1.15
Basic Average Shares
—
31.47
-1.52%
31.96
+0.00%
31.96
Diluted Average Shares
—
31.47
-1.52%
31.96
+0.00%
31.96
Diluted NI Availto Com Stockholders
-166.31
-106.62%
-80.49
-16.09%
-69.33
-87.86%
-36.91
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
333.17
+21.18%
274.94
+68.57%
163.10
-10.79%
182.83
Current Assets
332.90
+46.66%
226.98
+41.89%
159.97
-12.40%
182.62
Cash Cash Equivalents And Short Term Investments
312.82
+42.93%
218.86
+45.53%
150.39
-7.95%
163.37
Cash And Cash Equivalents
45.54
-38.70%
74.29
-50.60%
150.39
-7.95%
163.37
Cash Financial
—
—
—
163.37
Other Short Term Investments
267.28
+84.88%
144.57
0.00
—
Receivables
0.06
-88.00%
0.50
-34.30%
0.76
+52.20%
0.50
Other Receivables
0.06
—
0.24
+35.59%
0.18
Taxes Receivable
0.00
-100.00%
0.50
-34.30%
0.76
+52.20%
0.50
Prepaid Assets
—
7.62
-13.63%
8.82
-52.97%
18.75
Other Current Assets
20.02
+162.82%
7.62
-13.63%
8.82
-52.97%
18.75
Total Non Current Assets
0.27
-99.43%
47.96
+1432.36%
3.13
+1383.41%
0.21
Net PPE
0.01
-91.56%
0.15
-47.08%
0.29
+109.35%
0.14
Gross PPE
0.01
-91.56%
0.15
-47.08%
0.29
+109.35%
0.14
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.01
-91.56%
0.15
-47.08%
0.29
+109.35%
0.14
Investments And Advances
0.00
-100.00%
47.68
0.00
—
Non Current Deferred Assets
0.07
0.00
-100.00%
2.73
0.00
Other Non Current Assets
0.19
+50.79%
0.13
+17.76%
0.11
+48.61%
0.07
Total Liabilities Net Minority Interest
25.95
+50.08%
17.29
-94.53%
316.29
+18.04%
267.94
Current Liabilities
25.95
+50.20%
17.27
+48.61%
11.62
+39.04%
8.36
Payables And Accrued Expenses
19.39
+49.71%
12.95
+59.25%
8.13
+46.37%
5.55
Payables
5.93
+56.90%
3.78
-16.55%
4.53
+46.48%
3.09
Accounts Payable
5.93
+56.90%
3.78
-16.55%
4.53
+46.48%
3.09
Current Accrued Expenses
13.45
+46.74%
9.17
+154.71%
3.60
+46.24%
2.46
Pensionand Other Post Retirement Benefit Plans Current
6.54
+57.22%
4.16
+24.16%
3.35
+25.25%
2.68
Current Debt And Capital Lease Obligation
0.01
-91.36%
0.16
+15.71%
0.14
+9.38%
0.13
Current Capital Lease Obligation
0.01
-91.36%
0.16
+15.71%
0.14
+9.38%
0.13
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
0.01
-100.00%
304.67
+17.37%
259.58
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
0.01
-92.09%
0.18
+1509.09%
0.01
Long Term Capital Lease Obligation
0.00
-100.00%
0.01
-92.09%
0.18
+1509.09%
0.01
Preferred Securities Outside Stock Equity
—
0.00
-100.00%
304.49
+17.31%
259.57
Stockholders Equity
307.22
+19.24%
257.65
+268.19%
-153.19
-80.00%
-85.11
Common Stock Equity
307.22
+19.24%
257.65
+268.19%
-153.19
-80.00%
-85.11
Capital Stock
0.00
+33.33%
0.00
0.00
0.00
Common Stock
0.00
+33.33%
0.00
0.00
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
42.45
+25.95%
33.71
+5.48%
31.96
+0.00%
31.96
Ordinary Shares Number
42.45
+25.95%
33.71
+5.48%
31.96
+0.00%
31.96
Additional Paid In Capital
711.85
+43.46%
496.19
+10566.27%
4.65
+36.70%
3.40
Retained Earnings
-404.64
-69.78%
-238.33
-50.99%
-157.84
-78.33%
-88.51
Gains Losses Not Affecting Retained Earnings
0.01
+106.64%
-0.21
0.00
—
Other Equity Adjustments
0.01
+106.64%
-0.21
—
—
Total Equity Gross Minority Interest
307.22
+19.24%
257.65
+268.19%
-153.19
-80.00%
-85.11
Total Capitalization
307.22
+19.24%
257.65
+268.19%
-153.19
-80.00%
-85.11
Working Capital
306.95
+46.37%
209.71
+41.36%
148.34
-14.87%
174.26
Invested Capital
307.22
+19.24%
257.65
+268.19%
-153.19
-80.00%
-85.11
Total Debt
0.01
-92.05%
0.18
-44.48%
0.32
+128.06%
0.14
Capital Lease Obligations
0.01
-92.05%
0.18
-44.48%
0.32
+128.06%
0.14
Net Tangible Assets
307.22
+19.24%
257.65
+268.19%
-153.19
-80.00%
-85.11
Tangible Book Value
307.22
+19.24%
257.65
+268.19%
-153.19
-80.00%
-85.11
Other Equity Interest
—
—
—
—
Preferred Stock Equity
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-160.59
-128.72%
-70.21
-25.73%
-55.84
-27.99%
-43.63
Cash Flow From Continuing Operating Activities
-160.59
-128.72%
-70.21
-25.73%
-55.84
-27.99%
-43.63
Net Income From Continuing Operations
-166.31
-106.62%
-80.49
-16.09%
-69.33
-87.86%
-36.91
Other Non Cash Items
-3.03
—
—
—
Stock Based Compensation
12.52
+290.27%
3.21
+258.44%
0.90
+111.08%
0.42
Change In Working Capital
-3.77
-153.40%
7.07
-43.89%
12.60
+276.19%
-7.15
Change In Prepaid Assets
-12.56
-957.99%
1.46
-84.86%
9.67
+171.23%
-13.58
Change In Payables And Accrued Expense
8.81
+56.56%
5.63
+91.69%
2.94
-54.23%
6.41
Change In Accrued Expense
6.67
+4.55%
6.38
+309.83%
1.56
-56.93%
3.61
Change In Payable
2.14
+385.09%
-0.75
-154.46%
1.38
-50.75%
2.80
Change In Account Payable
2.14
+385.09%
-0.75
-154.46%
1.38
-50.75%
2.80
Change In Other Current Assets
0.00
+100.00%
-0.02
+42.86%
-0.04
-318.75%
0.02
Change In Other Current Liabilities
-0.02
-950.00%
-0.00
-108.00%
0.03
0.00
Investing Cash Flow
-71.23
+62.99%
-192.47
0.00
0.00
Cash Flow From Continuing Investing Activities
-71.23
+62.99%
-192.47
0.00
0.00
Net Investment Purchase And Sale
-71.23
+62.99%
-192.47
0.00
0.00
Purchase Of Investment
-272.93
-40.57%
-194.16
-676.66%
-25.00
0.00
Sale Of Investment
201.71
+11772.04%
1.70
-93.20%
25.00
0.00
Net Intangibles Purchase And Sale
—
—
—
0.00
Purchase Of Intangibles
—
—
—
0.00
Financing Cash Flow
203.06
+8.83%
186.58
+335.34%
42.86
-74.75%
169.72
Cash Flow From Continuing Financing Activities
203.06
+8.83%
186.58
+335.34%
42.86
-74.75%
169.72
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
202.63
+8.97%
185.95
0.00
-100.00%
0.00
Proceeds From Stock Option Exercised
0.50
-20.44%
0.63
+78.25%
0.35
+2260.00%
0.01
Net Other Financing Charges
-0.07
—
-2.41
—
Changes In Cash
-28.75
+62.21%
-76.10
-486.12%
-12.98
-110.30%
126.09
Beginning Cash Position
74.29
-50.60%
150.39
-7.95%
163.37
+338.23%
37.28
End Cash Position
45.54
-38.70%
74.29
-50.60%
150.39
-7.95%
163.37
Free Cash Flow
-160.59
-128.72%
-70.21
-25.73%
-55.84
-27.99%
-43.63
Common Stock Issuance
202.63
+8.97%
185.95
0.00
-100.00%
0.00
Issuance Of Capital Stock
202.63
+8.97%
185.95
+313.97%
44.92
-73.53%
169.71
Net Preferred Stock Issuance
—
0.00
-100.00%
44.92
-73.53%
169.71
Preferred Stock Issuance
—
0.00
-100.00%
44.92
-73.53%
169.71
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category